Fibrinolysis and coagulation in patients with infectious disease and sepsis
- Author
- Jan Philippé (UGent) , Fritz Offner (UGent) , PJ De Clerck, Geert Leroux-Roels (UGent) , Dirk Vogelaers (UGent) , Gaston Baele and D Collen
- Organization
- Abstract
- Sepsis is often associated with hemostatic dysfunction. This study aimed to relate changes in fibrinolysis and coagulation parameters to sepsis and sepsis outcome. Urokinase-type plasminogen activator (u-PA) antigen, tissue-type plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor (PAI) type 1 antigen, PAI activity, antithrombin (AT) III activity, and protein C activity were measured in 24 patients suffering from sepsis or septic shock and the results were compared with those observed in 30 non-sepsis patients with severe infectious disease. The u-PA level was markedly increased in plasma of sepsis patients as compared to non-sepsis patients (11.5 +/- 9.4 versus 1.6 +/- 1.5 ng/ml, p < 0.0001). PAI-1 antigen and t-PA activity showed a significant increase in sepsis patients (320 +/- 390 ng/ml versus 120 +/- 200 ng/ml, and 3.0 +/- 3.6 IU/ml versus 1.0 +/- 0.7 IU/ml, respectively, p < 0.01). AT III was decreased in sepsis patients (58 +/- 28% in sepsis versus 79 +/- 26% in severe infectious disease, p < 0.01) as was protein C (30 +/- 18% versus 58 +/- 27%, p < 0.001). No significant difference was found for t-PA antigen nor for PAI activity. Nonsurvivors of sepsis were distinguished mainly by a high u-PA antigen level and increased t-PA activity. It is concluded that plasma u-PA antigen showed the strongest significant difference, among the parameters evaluated, between sepsis and severe infection. u-PA antigen may be of prognostic value in patients admitted to the medical intensive care unit for severe infectious disease.
- Keywords
- UROKINASE ANTIGEN, DISSEMINATED INTRAVASCULAR COAGULATION, MURINE MONOCLONAL-ANTIBODIES, FAST-ACTING INHIBITOR, LINKED IMMUNOSORBENT-ASSAY, HUMAN-ENDOTHELIAL CELLS, THROMBOTIC THROMBOCYTOPENIC PURPURA, PLASMINOGEN-ACTIVATOR INHIBITOR-1, TISSUE-TYPE, PROTEIN-C LEVELS
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-308513
- MLA
- Philippé, Jan, et al. “Fibrinolysis and Coagulation in Patients with Infectious Disease and Sepsis.” THROMBOSIS AND HAEMOSTASIS, vol. 65, no. 3, 1991, pp. 291–95.
- APA
- Philippé, J., Offner, F., De Clerck, P., Leroux-Roels, G., Vogelaers, D., Baele, G., & Collen, D. (1991). Fibrinolysis and coagulation in patients with infectious disease and sepsis. THROMBOSIS AND HAEMOSTASIS, 65(3), 291–295.
- Chicago author-date
- Philippé, Jan, Fritz Offner, PJ De Clerck, Geert Leroux-Roels, Dirk Vogelaers, Gaston Baele, and D Collen. 1991. “Fibrinolysis and Coagulation in Patients with Infectious Disease and Sepsis.” THROMBOSIS AND HAEMOSTASIS 65 (3): 291–95.
- Chicago author-date (all authors)
- Philippé, Jan, Fritz Offner, PJ De Clerck, Geert Leroux-Roels, Dirk Vogelaers, Gaston Baele, and D Collen. 1991. “Fibrinolysis and Coagulation in Patients with Infectious Disease and Sepsis.” THROMBOSIS AND HAEMOSTASIS 65 (3): 291–295.
- Vancouver
- 1.Philippé J, Offner F, De Clerck P, Leroux-Roels G, Vogelaers D, Baele G, et al. Fibrinolysis and coagulation in patients with infectious disease and sepsis. THROMBOSIS AND HAEMOSTASIS. 1991;65(3):291–5.
- IEEE
- [1]J. Philippé et al., “Fibrinolysis and coagulation in patients with infectious disease and sepsis,” THROMBOSIS AND HAEMOSTASIS, vol. 65, no. 3, pp. 291–295, 1991.
@article{308513, abstract = {{Sepsis is often associated with hemostatic dysfunction. This study aimed to relate changes in fibrinolysis and coagulation parameters to sepsis and sepsis outcome. Urokinase-type plasminogen activator (u-PA) antigen, tissue-type plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor (PAI) type 1 antigen, PAI activity, antithrombin (AT) III activity, and protein C activity were measured in 24 patients suffering from sepsis or septic shock and the results were compared with those observed in 30 non-sepsis patients with severe infectious disease. The u-PA level was markedly increased in plasma of sepsis patients as compared to non-sepsis patients (11.5 +/- 9.4 versus 1.6 +/- 1.5 ng/ml, p < 0.0001). PAI-1 antigen and t-PA activity showed a significant increase in sepsis patients (320 +/- 390 ng/ml versus 120 +/- 200 ng/ml, and 3.0 +/- 3.6 IU/ml versus 1.0 +/- 0.7 IU/ml, respectively, p < 0.01). AT III was decreased in sepsis patients (58 +/- 28% in sepsis versus 79 +/- 26% in severe infectious disease, p < 0.01) as was protein C (30 +/- 18% versus 58 +/- 27%, p < 0.001). No significant difference was found for t-PA antigen nor for PAI activity. Nonsurvivors of sepsis were distinguished mainly by a high u-PA antigen level and increased t-PA activity. It is concluded that plasma u-PA antigen showed the strongest significant difference, among the parameters evaluated, between sepsis and severe infection. u-PA antigen may be of prognostic value in patients admitted to the medical intensive care unit for severe infectious disease.}}, author = {{Philippé, Jan and Offner, Fritz and De Clerck, PJ and Leroux-Roels, Geert and Vogelaers, Dirk and Baele, Gaston and Collen, D}}, issn = {{0340-6245}}, journal = {{THROMBOSIS AND HAEMOSTASIS}}, keywords = {{UROKINASE ANTIGEN,DISSEMINATED INTRAVASCULAR COAGULATION,MURINE MONOCLONAL-ANTIBODIES,FAST-ACTING INHIBITOR,LINKED IMMUNOSORBENT-ASSAY,HUMAN-ENDOTHELIAL CELLS,THROMBOTIC THROMBOCYTOPENIC PURPURA,PLASMINOGEN-ACTIVATOR INHIBITOR-1,TISSUE-TYPE,PROTEIN-C LEVELS}}, language = {{eng}}, number = {{3}}, pages = {{291--295}}, title = {{Fibrinolysis and coagulation in patients with infectious disease and sepsis}}, volume = {{65}}, year = {{1991}}, }